Insider Selling: ASP Isotopes (NASDAQ:ASPI) COO Sells 8,438 Shares

ASP Isotopes Inc. (NASDAQ:ASPI) COO Robert Ainscow sold 8,438 shares of the firm’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $4.29, for a total value of $36,199.02. Following the transaction, the chief operating officer owned 2,248,441 shares in the company, valued at approximately $9,645,811.89. This trade represents a 0.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Robert Ainscow also recently made the following trade(s):

• On Wednesday, September 2nd, Robert Ainscow sold 25,000 shares of ASP Isotopes stock. The stock was sold at an average price of $3.90, for a total transaction of $97,500.00.

ASP Isotopes Stock Performance

NASDAQ ASPI opened at $3.59 on Friday. The company has a fifty day moving average price of $4.21 and a 200-day moving average price of $5.16. The firm has a market cap of $550.38 million, a price-to-earnings ratio of -2.72 and a beta of 3.59. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.87 and a quick ratio of 3.85. ASP Isotopes Inc. has a 1 year low of $3.51 and a 1 year high of $14.49.

ASP Isotopes (NASDAQ:ASPI) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.11). ASP Isotopes had a negative net margin of 427.98% and a negative return on equity of 64.99%. The firm had revenue of $5.12 million for the quarter, compared to the consensus estimate of $4.47 million.

Analysts Set New Price Targets

Several equities analysts have commented on ASPI shares. Wall Street Zen raised shares of ASP Isotopes from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ASP Isotopes in a report on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, ASP Isotopes currently has a consensus rating of “Hold” and a consensus target price of $13.00.

Institutional Investors Weigh In On ASP Isotopes

Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in shares of ASP Isotopes during the second quarter valued at about $57,331,000. Encompass Capital Advisors LLC bought a new position in shares of ASP Isotopes in the first quarter valued at approximately $30,551,000. Alyeska Investment Group L.P. grew its stake in ASP Isotopes by 73.4% during the fourth quarter. Alyeska Investment Group L.P. now owns 4,895,546 shares of the company’s stock valued at $26,191,000 after acquiring an additional 2,072,851 shares in the last quarter. AWM Investment Company Inc. purchased a new position in ASP Isotopes during the second quarter valued at approximately $9,837,000. Finally, UBS Group AG increased its holdings in ASP Isotopes by 150.3% during the 4th quarter. UBS Group AG now owns 2,406,457 shares of the company’s stock worth $12,875,000 after acquiring an additional 1,445,165 shares during the period. Hedge funds and other institutional investors own 16.80% of the company’s stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.